Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1

H Innes, S Buch, S Hutchinson, IN Guha, JR Morling… - Gastroenterology, 2020 - Elsevier
H Innes, S Buch, S Hutchinson, IN Guha, JR Morling, E Barnes, W Irving, E Forrest…
Gastroenterology, 2020Elsevier
Background and Aims Little is known about genetic factors that affect development of
alcohol-related cirrhosis. We performed a genome-wide association study (GWAS) of
samples from the United Kingdom Biobank (UKB) to identify polymorphisms associated with
risk of alcohol-related liver disease. Methods We performed a GWAS of 35,839 participants
in the UKB with high intake of alcohol against markers of hepatic fibrosis (FIB-4, APRI, and
Forns index scores) and hepatocellular injury (levels of aminotransferases). Loci identified in …
Background and Aims
Little is known about genetic factors that affect development of alcohol-related cirrhosis. We performed a genome-wide association study (GWAS) of samples from the United Kingdom Biobank (UKB) to identify polymorphisms associated with risk of alcohol-related liver disease.
Methods
We performed a GWAS of 35,839 participants in the UKB with high intake of alcohol against markers of hepatic fibrosis (FIB-4, APRI, and Forns index scores) and hepatocellular injury (levels of aminotransferases). Loci identified in the discovery analysis were tested for their association with alcohol-related cirrhosis in 3 separate European cohorts (phase 1 validation cohort; n=2545). Variants associated with alcohol-related cirrhosis in the validation at a false discovery rate of less than 20% were then directly genotyped in 2 additional European validation cohorts (phase 2 validation, n=2068).
Results
In the GWAS of the discovery cohort, we identified 50 independent risk loci with genome-wide significance (P < 5 × 10−8). Nine of these loci were significantly associated with alcohol-related cirrhosis in the phase 1 validation cohort; 6 of these 9 loci were significantly associated with alcohol-related cirrhosis in phase 2 validation cohort, at a false discovery rate below 5%. The loci included variants in the mitochondrial amidoxime reducing component 1 gene (MARC1) and the heterogeneous nuclear ribonucleoprotein U like 1 gene (HNRNPUL1). After we adjusted for age, sex, body mass index, and type-2 diabetes in the phase 2 validation cohort, the minor A allele of MARC1:rs2642438 was associated with reduced risk of alcohol-related cirrhosis (adjusted odds ratio, 0.76; P=.0027); conversely, the minor C allele of HNRNPUL1:rs15052 was associated with an increased risk of alcohol-related cirrhosis (adjusted odds ratio, 1.30; P=.020).
Conclusions
In a GWAS of samples from the UKB, we identified and validated (in 5 European cohorts) single-nucleotide polymorphisms that affect risk of alcohol-related cirrhosis in opposite directions: the minor A allele in MARC1:rs2642438 decreases risk, whereas the minor C allele in HNRNPUL1:rs15052 increases risk.
Elsevier